# Fabry disease FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/fabry-disease

> No upcoming FDA catalysts in Fabry disease; 5 past events are recorded.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA decisions for Fabry disease?

No upcoming FDA catalysts in Fabry disease; 5 past events are recorded. ClinicalTrials.gov: "NCT05280548 (A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-05-22 (ACTUAL); Lead Sponsor Sanofi." [Calendar and source filings](https://sec-api.dev/indications/fabry-disease)

Source: ClinicalTrials.gov, https://clinicaltrials.gov/study/NCT05280548 (retrieved 2026-11-16). Last confirmed 2026-11-16T22:20:01.192Z. Cite: https://sec-api.dev/indications/fabry-disease#answer

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| April 4, 2022 | [Elfabrio (pegunigalsidase alfa) topline data readout](https://sec-api.dev/pdufa/pegunigalsidase-alfa) | PLX | Fabry disease | completed, positive | "On April 4, 2022, we, together with our development and commercialization partner for PRX-102, Chiesi, announced positive topline results from our BALANCE study, a pivotal phase III clinical trial evaluating PRX-102, 1 mg/kg, administered every two weeks, compared to agalsidase beta (Fabrazyme®) for the treatment of Fabry disease." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1006281/000110465925024457/tm259263d1_424b5.htm)) |
| Aug 2024 | [AMT-191 trial start](https://sec-api.dev/pdufa/amt-191) | QURE | Fabry disease | completed | "In August 2024, we announced that the first patient has been dosed." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1590560/000155837025009694/qure-20250630x10q.htm)) |
| December 17, 2025 | [Venglustat (gz402671) primary completion](https://sec-api.dev/pdufa/venglustat-gz402671) | SNY | Fabry Disease | completed | "NCT05206773 (A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-12-17 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05206773)) |
| 1H 2026 | [AMT-191 interim data readout](https://sec-api.dev/pdufa/amt-191) | QURE | Fabry disease | scheduled | "~ Presented initial data from Phase I/IIa study of AMT-191 in Fabry disease showing sustained increases in α - gal enzyme activity in patients with Fabry disease; additional clinical data expected in the first half of 2026 ~" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590560/000110465925108802/qure-20251110xex99d1.htm)) |
| May 22, 2026 | [Venglustat (gz402671) primary completion](https://sec-api.dev/pdufa/venglustat-gz402671) | SNY | Fabry Disease | completed | "NCT05280548 (A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-05-22 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05280548)) |

## Drugs

- [Elfabrio (pegunigalsidase alfa)](https://sec-api.dev/pdufa/pegunigalsidase-alfa) (PLX)
- [AMT-191](https://sec-api.dev/pdufa/amt-191) (QURE)
- [Venglustat (gz402671)](https://sec-api.dev/pdufa/venglustat-gz402671) (SNY)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/fabry-disease.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Fabry disease FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/fabry-disease

```bibtex
@misc{secapidev_indications_fabry_disease_20261116,
  title        = {Fabry disease FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/fabry-disease}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_fabry_disease_20261116","title":"Fabry disease FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/fabry-disease","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
